Clinical Research Directory
Browse clinical research sites, groups, and studies.
External Sensing and Neuromodulation to Assess Diabetic Pain Outcomes (XANADO)
Sponsor: Abbott Medical Devices
Summary
This is a prospective, longitudinal, single-center, non-randomized, open-label, post-market clinical feasibility study to assess the efficacy of neuromodulation therapies (SCS and DRG) for chronic pain patients with diabetes and investigate whether physical and physiological data collected from diabetic and pre-diabetic chronic pain patients is predictive of subjective patient-reported outcomes (PROs) and of adjustments in patient care. These assessments will be made prior to, during, and after the trial of the SCS or DRG system. The study will be carried out in the United States at a single site.
Official title: External Sensing and Neuromodulation to Assess Diabetic Pain Outcomes
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2023-06-06
Completion Date
2025-04
Last Updated
2024-07-12
Healthy Volunteers
No
Conditions
Interventions
Standard of care neuromodulation therapy (SCS or DRG)
Standard SCS or DRG therapy
Locations (1)
Rush University Medical Center
Chicago, Illinois, United States